Aquestive Therapeutics

$6.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+0.59%) Today
+$0.03 (+0.44%) As of 5:42 AM EST after-hours

Why Robinhood?

You can buy or sell AQST and other stocks, options, and ETFs commission-free!

About AQST

Aquestive Therapeutics, Inc. Common Stock, also called Aquestive Therapeutics, is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ. The listed name for AQST is Aquestive Therapeutics, Inc. Common Stock.

CEO
Keith J. Kendall
Employees
232
Headquarters
Warren, New Jersey
Founded
2004
Market Cap
227.94M
Price-Earnings Ratio
Dividend Yield
Average Volume
715.73K
High Today
$7.08
Low Today
$6.70
Open Price
$7.00
Volume
465.69K
52 Week High
$10.00
52 Week Low
$1.41

Collections

AQST Earnings

-$0.82
-$0.55
-$0.27
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 10, After Hours

You May Also Like